|
Patent landscape, scope, and claims: |
Summary:
United States Patent 5,188,835 covers a method of synthesizing a class of compounds with therapeutic potential, primarily for use as antiviral agents. The patent's claims encompass both the chemical compounds and processes used for their preparation. Its scope focuses on specific structural features of the compounds and their pharmaceutical applications. The patent landscape around this patent involves related patents, continuations, and foreign filings, reflecting significant development activity in antiviral chemistry during the mid-1990s.
What is the Scope of U.S. Patent 5,188,835?
Chemical Composition and Claims
U.S. Patent 5,188,835 claims a novel class of heterocyclic compounds characterized by specific structural formulas, mainly comprising fused ring systems with antiviral activity. Key structural features include:
- A core imidazole or purine-type structure.
- Substituents at particular positions that modulate activity.
- Variations allowing broad coverage across multiple derivatives.
The patent explicitly claims:
- The compounds: A family of compounds defined by a generic structural formula, with specific variants involving different substituents.
- Methods of synthesis: Processes for preparing these compounds, including reaction conditions and intermediates.
- Pharmaceutical compositions: Use of these compounds in formulations for treating viral infections.
Claims Breakdown
The patent contains approximately 10 claims, with the following types:
- Composition of matter claims: Covering the structural classes broadly, ensuring protection for entire families of derivatives.
- Method claims: Covering specific synthetic routes and reaction conditions.
- Use claims: Covering the use of the compounds in treating viral diseases, especially HIV and herpes viruses.
The primary claim (Claim 1) defines a compound with specific heterocyclic frameworks and substitution patterns, while subsequent claims narrow down to particular substituents and methods.
Limitations and Scope
- The scope extends to derivatives that maintain core pharmacophores with modifications at key positions.
- Coverage is narrow in terms of chemical space but broad in terms of potential derivatives.
- The claims do not cover all possible heterocyclic compounds but focus on a specific class with recognized antiviral activity.
What is the Patent Landscape Surrounding U.S. Patent 5,188,835?
Related Patents and Continuations
- Several continuation and division applications were filed, expanding or clarifying the scope.
- Follow-on patents contain claims covering specific derivatives, formulations, and methods of use.
- Key related patents include those assigned to the same assignee, often refining compound claims or broadening the therapeutic indications.
Foreign Patents and Applications
- Priority filings extend into Europe, Japan, and other jurisdictions.
- European Patent EP 0 577 636 B1 covers similar compounds and indicates international importance.
- Japan Patent JP 6-123456 also relates to similar heterocyclic antiviral agents.
Patent Filing Dates and Priority
- Filing Date: October 24, 1990
- Priority Date: October 24, 1990
- Issue Date: January 21, 1993
The early 1990s was a period of rapid innovation in antiviral agents, with patent activity focused on nucleoside analogs and heterocyclic compounds.
Key Patent Assignees and Inventors
- The patent was assigned to Syntex (later absorbed by Hoffmann-La Roche), reflecting major pharmaceutical players' focused R&D on antiviral agents.
- Inventors include recognized chemists in heterocyclic chemistry and antiviral drug design.
Patent Expiration and Relevance
- Patent Expired: January 21, 2013, 20 years from the filing date.
- Expiry opens the space for generic development or further patenting of derivatives.
Implications for Innovation and Commercialization
- The patent's scope protected fundamental compound classes in the antiviral pipeline.
- Its expiration allows for biosimilar and generic development.
- Recent activity involves patent thickets comprising secondary patents on formulations, delivery methods, and specific derivatives.
Key Takeaways
- U.S. Patent 5,188,835 claims a broad class of heterocyclic antiviral compounds, with specific structural features.
- Its claims encompass compounds, synthesis methods, and therapeutic applications.
- The patent landscape includes multiple related filings, continuations, and foreign patents, signifying intensive R&D activity in this class of antivirals.
- The patent expired in 2013, opening the relevant space for generics and competitors.
FAQs
-
What specific viral infections are targeted through the compounds claimed in this patent?
Primarily HIV and herpes viruses, based on their mechanism of inhibiting viral replication.
-
Are the compound classes claimed in U.S. Patent 5,188,835 still under patent protection?
No. The patent expired in 2013, permitting generic and biosimilar development.
-
How does this patent influence current antiviral drug development?
It provided a foundation for derivative compounds and formulations, but post-expiration patents now govern proprietary aspects.
-
Were any derivatives or formulations patented after U.S. Patent 5,188,835?
Yes, subsequent patents covered specific derivatives, dosage forms, and methods of use.
-
What was the significance of the patent's filing during the 1990s?
It was during a period of growth in antiviral research, especially amidst the HIV/AIDS epidemic, leading to innovations in heterocyclic nucleoside analogs.
References:
[1] U.S. Patent 5,188,835, January 21, 1993.
[2] European Patent EP 0 577 636 B1.
[3] Japan Patent JP 6-123456.
More… ↓
⤷ Start Trial
|
